Neuromodulation in Patients With Neuropathic Pain and Depression.

Who May Qualify: - Central or peripheral neuropathic pain - Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale - Pain present on a daily or near-daily basis (at least 4 days a week) - Patient not completely relieved by recommended drug treatments for first- and second-line neuropathic pain - Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month, and will not need to be modified for the duration of the study. - Patient with a depressive episode characterized according to DSM V criteria - Indication for motor cortex rTMS by a neurologist - Patient can be followed for the entire duration of the study - Patient having received willing to sign a consent form to participate in the study, and having co-signed a consent form with the investigator - Member or beneficiary of a social security scheme Who Should NOT Join This Trial: - Industrial accident or litigation - Contraindication to rTMS or MRI (seismotherapy treatment since the previous month; epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia) - Drug or psychoactive substance abuse - Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemic disease disease) - Presence of other pain more severe than that justifying inclusion - Patient unable to understand willing to sign a consent form - Patient unwilling or unable to stop treatments prohibited during the study - Patient participating in another research protocol involving a drug within the 30 days prior to inclusion - Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice safeguard, family safeguard) - Minor patient Always talk to your doctor about whether this trial is right for you.